[Recent problems on the endocrine and chemotherapy].
The endometrial carcinoma, as well as the breast cancers and some kinds of ovarian cancers, was considered to a hormone dependent carcinoma. Even if we tried to do the endocrine therapy using such as medroxy progesterone acetate (MPA), we could expect only 30% of anti-tumor effects on the endometrial carcinoma. Endocrine therapy was thought to have a different action mechanisms from the other anti-cancer drugs. Whereas cisplatin (CDDP) has strongly an effectiveness for ovarian cancers, but the drug resistance of cancer cells for CDDP was causing a serious problem. This paper will be discussed about the problems of the endocrine and chemotherapy from the point of view of cell cycle analysis. Additionally, we would like to describe about the new anticancer drug such as Taxol.
Nishiya
I
I
Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka-City, Japan.
Yoshizaki
A
A
Satoh
K
K
Matsuta
M
M
Fukushima
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002453:Cell Cycle / Q000502:physiology*; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D017239:Paclitaxel / Q000627:therapeutic use
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D017258:Medroxyprogesterone Acetate; D017239:Paclitaxel; D002945:Cisplatin